A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Pfizer

Status and phase: Completed; Phase 2

Conditions: Acne Inversa

Treatments: Drug: PF-06826647; Drug: Placebo; Drug: PF-06650833; Drug: PF-06700841

Study type: Interventional

Funder types: Industry

Identifiers

NCT04092452

C2501007

Details and patient eligibility

About

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Enrollment: 194 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa

Exclusion criteria

• History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
• Infected with hepatitis B or hepatitis C viruses.
• Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

194 participants in 4 patient groups, including a placebo group

Cohort 1

Experimental group

Description:

PF-06650833

Treatment:

Drug: PF-06650833

Cohort 2

Experimental group

Description:

PF-6700841

Treatment:

Drug: PF-06700841

Cohort 3

Experimental group

Description:

PF-06826647

Treatment:

Drug: PF-06826647

Cohort placebo

Placebo Comparator group

Description:

placebo

Treatment:

Drug: Placebo